Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$339.30
+0.6%
$345.86
$267.83
$391.29
$183.11B0.442.74 million shs1.47 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$418.57
-0.1%
$399.10
$356.28
$555.45
$3.11T1.135.29 million shs22.00 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.92
-0.1%
$26.88
$22.88
$28.75
$147.72B0.3541.85 million shs22.18 million shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.76%+0.35%-2.16%-9.96%+24.35%
Microsoft Corporation stock logo
MSFT
Microsoft
-0.47%+2.36%-1.20%+5.50%-7.40%
Pfizer Inc. stock logo
PFE
Pfizer
+0.57%+0.72%-5.09%-2.74%+12.43%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$339.30
+0.6%
$345.86
$267.83
$391.29
$183.11B0.442.74 million shs1.47 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$418.57
-0.1%
$399.10
$356.28
$555.45
$3.11T1.135.29 million shs22.00 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.92
-0.1%
$26.88
$22.88
$28.75
$147.72B0.3541.85 million shs22.18 million shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.76%+0.35%-2.16%-9.96%+24.35%
Microsoft Corporation stock logo
MSFT
Microsoft
-0.47%+2.36%-1.20%+5.50%-7.40%
Pfizer Inc. stock logo
PFE
Pfizer
+0.57%+0.72%-5.09%-2.74%+12.43%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$355.194.68% Upside
Microsoft Corporation stock logo
MSFT
Microsoft
2.85
Moderate Buy$560.8834.00% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.6110.39% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AMGN, MSFT, PFE, and SGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingBuy
5/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetBuy$400.00 ➝ $375.00
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/14/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetOverweight$432.00 ➝ $427.00
5/13/2026
Amgen Inc. stock logo
AMGN
Amgen
Lower Price TargetOutperform$410.00 ➝ $390.00
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingOutperform$575.00
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
UpgradeBuy$485.00
5/7/2026
Amgen Inc. stock logo
AMGN
Amgen
UpgradeHoldStrong-Buy
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Lower Price Target$678.00 ➝ $573.00
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingBuy
5/6/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price TargetBuy$595.00 ➝ $680.00
(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B4.98$34.59 per share9.81$17.03 per share19.92
Microsoft Corporation stock logo
MSFT
Microsoft
$281.72B11.04$18.18 per share23.02$55.78 per share7.50
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.42 per share5.87$15.86 per share1.63
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$14.3723.6114.403.3320.96%137.41%13.28%8/4/2026 (Estimated)
Microsoft Corporation stock logo
MSFT
Microsoft
$101.83B$16.8024.9121.701.5239.34%31.94%18.47%7/29/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.799.06N/A11.83%19.44%8.41%8/4/2026 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest AMGN, MSFT, PFE, and SGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Amgen Inc. stock logo
AMGN
Amgen
$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion
4/29/2026Q3 2026
Microsoft Corporation stock logo
MSFT
Microsoft
$4.06$4.27+$0.21$4.27$81.44 billion$82.89 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.97%+8.27%70.15%14 Years
Microsoft Corporation stock logo
MSFT
Microsoft
$3.640.87%+10.24%21.67%23 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.64%-13.20%131.30%16 Years
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A

Latest AMGN, MSFT, PFE, and SGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
3/10/2026
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.910.87%5/21/20265/21/20266/11/2026
3/4/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.523.09%5/15/20265/15/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
5.65
1.26
1.01
Microsoft Corporation stock logo
MSFT
Microsoft
0.08
1.28
1.27
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500539.68 million535.10 millionOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionNo Data

Recent News About These Companies

Merck in "advanced talks" for $40bn Seagen bid; report
Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Pfizer raises guidance as COVID franchise drives Q3 beat
Franklin Biotechnology Discovery C
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Pfizer: Turning The Corner (Rating Upgrade)
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$339.30 +1.88 (+0.56%)
Closing price 04:00 PM Eastern
Extended Trading
$341.15 +1.85 (+0.54%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$418.57 -0.52 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$418.65 +0.08 (+0.02%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

Pfizer stock logo

Pfizer NYSE:PFE

$25.92 -0.03 (-0.12%)
Closing price 03:59 PM Eastern
Extended Trading
$25.92 +0.01 (+0.02%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.